Fighting fire with fire: Rewiring tumor cells for oncolytic virotherapy

Future Oncology

Volumn 8, Issue 3, 2012, Pages 219-221

  Mahoney, Douglas J ^a,b   Stojdl, David F ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

cell stress; endoplasmic reticulum; oncolytic virus; resistance; RNAi screens

Indexed keywords

CRADD PROTEIN; ONCOLYTIC VIRUS; TUMOR ANTIGEN;

CELL ENGINEERING; CHRONIC MYELOID LEUKEMIA; CYTOKINE RESPONSE; DNA DAMAGE; ENDOPLASMIC RETICULUM; GENE MUTATION; HUMAN; MITOSIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TUMOR CELL; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84858377847     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.2     Document Type: Review

References (20)

1. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002
2. Jain M, Arvanitis C, Chu K et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104 (2002
3. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565-577 (1999
4. Chin L, Tam A, Pomerantz J et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999
5. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002
6. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002
7. Auer R, Bell JC. Oncolytic viruses: Smart therapeutics for smart cancers. Future Oncol. 8, 1-4 (2012
8. Stojdl DF, Lichty BD, tenOever BR et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275 (2003
9. Stojdl DF, Lichty B, Knowles S et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825 (2000
10. Breitbach CJ, Paterson JM, Lemay CG et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693 (2007
11. Prestwich RJ, Ilett EJ, Errington F et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 15, 4374-4381 (2009
12. Breitbach CJ, Burke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011
13. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A Phase I trial. Lancet Oncol. 9, 533-542 (2008
14. Mahoney DJ, Stojdl DF. Potentiating oncolytic viruses by targeted drug intervention. Curr. Opin Mol. Ther. 12, 394-402 (2010
15. Kondo N, Tsukuda M, Kimura M et al. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol. Rep. 23, 355-363 (2010)
16. Alain T, Lun X, Martineau Y et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl Acad. Sci. USA 107, 1576-1581 (2010)
17. Mahoney DJ, Lefebvre C, Allan K et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20, 443-456 (2011)
18. Brun J, McManus D, Lefebvre C et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18, 1440-1449 (2010)
19. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136, 823-837 (2009)
20. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986-988 (2007)